Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmad Awada

Showing results (201-210 of 311) with videos related to

Pageof 32
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 27, 2022
Corrigendum to 'p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib'[Eur J of Cancer 55 (2016) 98-110]Mohammad Krayem, Fabrice Journe, Murielle Wiedig, et al.
Clinical Breast Cancer|June 9, 2016
Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G GeneAhmad Awada, Javier Cortés, Miguel Martín, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 20, 2012
EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinomaYassine Lalami, Pol M Specenier, Ahmad Awada, et al.
Cells|November 26, 2022
Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug ResistancePashalina Kehagias, Nadège Kindt, Mohammad Krayem, et al.
Breast Cancer Research and Treatment|October 8, 2016
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation studySara M Tolaney, Hovav Nechushtan, Ilan-Gil Ron, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2013
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancerMiguel Martin, Jacques Bonneterre, Charles E Geyer, et al.
Breast Cancer Research : BCR|July 9, 2016
"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapyChristopher Twelves, Javier Cortes, Peter A Kaufman, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2012
Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumoursAhmad Awada, Alain Hendlisz, Olaf Christensen, et al.
Cancer Chemotherapy and Pharmacology|September 16, 2008
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patientsJürgen B Bulitta, Ping Zhao, Robert D Arnold, et al.
Cancer Chemotherapy and Pharmacology|December 10, 2015
A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumorsPatrick Schöffski, Philippe Aftimos, Herlinde Dumez, et al.
Pageof 32

Showing results (201-210 of 311) with videos related to

Sort By:
Pageof 32
European Journal of Cancer (Oxford, England : 1990)|September 27, 2022
Corrigendum to 'p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib'[Eur J of Cancer 55 (2016) 98-110]Mohammad Krayem, Fabrice Journe, Murielle Wiedig, et al.
Clinical Breast Cancer|June 9, 2016
Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G GeneAhmad Awada, Javier Cortés, Miguel Martín, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 20, 2012
EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinomaYassine Lalami, Pol M Specenier, Ahmad Awada, et al.
Cells|November 26, 2022
Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug ResistancePashalina Kehagias, Nadège Kindt, Mohammad Krayem, et al.
Breast Cancer Research and Treatment|October 8, 2016
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation studySara M Tolaney, Hovav Nechushtan, Ilan-Gil Ron, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2013
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancerMiguel Martin, Jacques Bonneterre, Charles E Geyer, et al.
Breast Cancer Research : BCR|July 9, 2016
"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapyChristopher Twelves, Javier Cortes, Peter A Kaufman, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2012
Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumoursAhmad Awada, Alain Hendlisz, Olaf Christensen, et al.
Cancer Chemotherapy and Pharmacology|September 16, 2008
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patientsJürgen B Bulitta, Ping Zhao, Robert D Arnold, et al.
Cancer Chemotherapy and Pharmacology|December 10, 2015
A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumorsPatrick Schöffski, Philippe Aftimos, Herlinde Dumez, et al.
Pageof 32